脑膜瘤与乳腺癌:同时性和异时性脑膜瘤与乳腺癌患者的生存分析
基于SEER数据库纳入1715例脑膜瘤与乳腺癌患者(中位随访84个月),按肿瘤出现顺序分为乳腺癌先于脑膜瘤、同时性、脑膜瘤先于乳腺癌三组。同时性组生存期最短(中位32个月),乳腺癌先于脑膜瘤组最长(中位110个月);未校正分析同时性组HR为3.13(95%CI 1.62-6.04),校正后HR为3.11(95%CI 1.58-6.19),异时性两组间无统计学差异。
要点
- 同时性乳腺癌+脑膜瘤患者生存期最短,中位32个月,乳腺癌先于脑膜瘤组最长,中位110个月。
- 校正分析显示同时性组死亡风险显著高于乳腺癌先于脑膜瘤组(HR 3.11,95%CI 1.58-6.19)。
- 年龄增加(HR 1.13,95%CI 1.11-1.15)和Ⅲ级脑膜瘤(HR 4.51,95%CI 1.90-10.69)与更低生存相关。
核心结论
- 同时性肿瘤与更低生存相关,年龄增加对患者生存有负面影响。
- 乳腺癌的手术与放疗联合治疗对结局有正面影响(HR 0.37,95%CI 0.23-0.93,p<0.05),而脑膜瘤治疗与生存无关(p>0.05)。
- Ⅲ级脑膜瘤和激素受体状态仅影响同时性肿瘤患者的生存(p<0.05),对异时性肿瘤生存无影响(p>0.05)。
研究设计与样本
- 使用SEER数据库的回顾性研究,共纳入1715例同时患有乳腺癌和脑膜瘤的患者。
- 按肿瘤出现顺序分为三组:乳腺癌先于脑膜瘤(组1)、同时性乳腺癌+脑膜瘤(组2)、乳腺癌后于脑膜瘤(组3)。
- 中位随访84个月,分析人口学、脑膜瘤和乳腺癌变量,主要结局为肿瘤学生存。
主要发现
- 组2生存期最短(中位32个月),组1最长(中位110个月)。
- 未校正分析中组2生存期最短(HR 3.13,95%CI 1.62-6.04),校正分析证实该发现(HR 3.11,95%CI 1.58-6.19),异时性肿瘤组间无统计学差异。
- 年龄增加(HR 1.13,95%CI 1.11-1.15,p<0.005)和Ⅲ级脑膜瘤(HR 4.51,95%CI 1.90-10.69,p<0.005)与更低生存相关。
- 脑膜瘤治疗对生存无影响(p>0.05)。
- 乳腺癌治疗中手术与放疗联合改善结局(HR 0.37,95%CI 0.23-0.93,p<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The prognosis of the association between Breast Cancer (BC) and Meningioma (M) is unknown. To evaluate the survival impact of tumor exposure sequence in patients with both tumors. Patients were divided in groups according to the tumors sequence: BC before M (group 1), synchronous BC + M (group 2) and BC after M (group 3). The SEER database was used. Demographics, meningioma and breast cancer variables were analyzed. The primary outcome was oncological survival. A total of 1715 patients were included (median follow-up:84 months). Group 2 had the shortest survival (median:32 months) and group 1 the longest (median:110 months). On the unadjusted analysis, group 2 had the shortest survival (HR:3.13, 95% CI 1.62-6.04) and adjusted analysis confirmed this finding (HR 3.11, 95% CI 1.58-6.19), with no statistical difference between the metachronous tumors groups. Increasing age (HR:1.13, 95% CI 1.11-1.15, p < 0.005) and grade III meningioma (HR:4.51, 95% CI 1.90-10.69, p < 0.005) were related with lower survival. Meningioma treatment had no influence on the survival (p > 0.05). The association between surgery and radiotherapy in BC treatment improved the outcome (HR 0.37, 95% CI 0.23-0.93, p < 0.05). Grade III meningioma and receptor hormonal status influenced synchronous tumors (p < 0.05) but had no influence on metachronous tumors survival (p > 0.05) on stratified analysis. Synchronous tumors were associated with lower survival. Increasing age had a negative influence on patient survival. Although surgery and radiotherapy for breast cancer had a positive influence in the outcome, meningioma treatment was not related with survival. Grade III meningioma and hormonal receptor status only influenced synchronous tumors patient survival.
引用
- Lavrador JP, Pinto MV, Lemos LM, et al. Meningioma and breast cancer: survival of patients with synchronous and metachronous meningioma and breast cancer. J Neurooncol. 2017. PMID: 29119423. doi:10.1007/s11060-017-2640-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。